11 August 2025 in Clinical Cancer Research
PURPOSE: This study evaluated the safety, tolerability, and preliminary efficacy of M1-c6v1, an oncolytic virus, combined with the immune checkpoint inhibitors (ICIs) camrelizumab and the vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor apatinib in advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: This single-arm, investigator-initiated, open-label clinical trial enrolled patients with advanced HCC (NCT04665362). Patients received M1-c6v1 (1×10⁹ CCID50) intravenously for 5 days every 28 days, camrelizumab (200 mg) intravenously biweekly, and apatinib (250 mg) orally daily. Treatment continued for up to 1 year or until disease progression, intolerability, or withdrawal. Primary endpoints were safety and tolerability, while secondary endpoints assessed efficacy based on tumor response, progression-free survival (PFS), and overall survival (OS). RESULTS: Thirteen patients were enrolled, with 84.6% having hepatitis B virus (HBV)-related HCC and 76.9% presenting with tumors >10 cm. The treatment was well-tolerated, with 92.15% of adverse events (AEs) being grade 1 or 2. The most common AEs included influenza-like symptoms and transient cytopenia. No viral shedding was detected in all secretions and excretions collected from subjects. In 10 patients evaluable for efficacy, the overall response rate (ORR) was 70% (7/10), with 7 partial responses (PR) according to mRECIST. The median OS and PFS was 15.4 and 8.9 months respectively. CONCLUSION: The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC.
7 May 2026 in Journal of Medical Virology
Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response. In this randomized controlled trial, HBeAg‐positive patients with normal ALT and elevated HBV DNA were randomly allocated 1:1 to receive TAF 25 mg/day or observation. The primary endpoint was the decline from baseline in HBsAg at Week 48. Secondary endpoints included HBV DNA response rates and the magnitude of HBV DNA reduction. The treatment group was further divided into virological response (VR) and low‐level viremia (LLV) subgroups based on HBV DNA response at Week 48. PBMCs from VR ( n = 3) and LLV ( n = 3) patients underwent scRNA‐seq for comparative immunological analysis. A total of 59 patients were allocated to the treatment ( n = 30) and control ( n = 29) groups. No serious adverse events occurred, except for one control patient who developed an ALT flare and required antiviral initiation. At Week 48, the treatment group demonstrated significantly greater reductions in HBsAg (0.19 vs. 0 log10 IU/mL, p = 0.005) and HBV DNA (6.32 vs. 0.19 log10 IU/mL, p < 0.001) compared to controls. In the treatment group, 20% achieved HBV DNA < 20 IU/mL and 3.3% achieved HBeAg seroconversion, while none occurred in the untreated patients. PBMCs scRNA‐seq revealed dominant distributions of NK_FCER1G, NK_KLRF1, NK_XCL1, and NKT_FCGR3A subclusters in the VR group, with upregulated expression of genes such as SLC27A4 and PTMA . Taken together, our findings revealed that TAF demonstrates favorable safety and antiviral efficacy in patients with high‐replicative, low‐inflammatory HBV infection during the 48‐week follow‐up period, although complete virological suppression rates remain suboptimal. NK‐mediated mechanisms may contribute to antiviral success. Trial Registration: The trial was registered on ClinicalTrials.gov (NCT 04231565).